These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21117058)

  • 1. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
    Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S
    Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
    Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
    BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for the treatment of sickle cell disease.
    Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
    Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.
    Oyeku SO; Driscoll MC; Cohen HW; Trachtman R; Pashankar F; Mullen C; Giardina PJ; Velazco N; Racine AD; Green NS
    Pediatr Blood Cancer; 2013 Apr; 60(4):653-8. PubMed ID: 23129068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    de Montalembert M; Voskaridou E; Oevermann L; Cannas G; Habibi A; Loko G; Joseph L; Colombatti R; Bartolucci P; Brousse V; Galactéros F;
    Am J Hematol; 2021 Oct; 96(10):1223-1231. PubMed ID: 34224583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
    Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
    Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
    Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
    Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.
    Sinha CB; Bakshi N; Ross D; Krishnamurti L
    PLoS One; 2018; 13(6):e0199375. PubMed ID: 29949647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
    Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
    J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do difficulties in swallowing medication impede the use of hydroxyurea in children?
    Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS
    Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
    Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
    Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.